<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmacoepidemiol Drug Saf</journal-id><journal-id journal-id-type="iso-abbrev">Pharmacoepidemiol Drug Saf</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Pharmacoepidemiology and drug safety</journal-title></journal-title-group><issn pub-type="ppub">1053-8569</issn><issn pub-type="epub">1099-1557</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10052807</article-id><article-id pub-id-type="pmcid-ver">PMC10052807.1</article-id><article-id pub-id-type="pmcaid">10052807</article-id><article-id pub-id-type="pmcaiid">10052807</article-id><article-id pub-id-type="manuscript-id">NIHMS1881734</article-id><article-id pub-id-type="pmid">35695189</article-id><article-id pub-id-type="doi">10.1002/pds.5495</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1881734</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1881734</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Association between opioid therapy trajectories and potential opioid-related adverse health events</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Hayes</surname><given-names initials="CJ">Corey J.</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-4043-2583</contrib-id><name name-style="western"><surname>Koonce</surname><given-names initials="RM">Ruston M.</given-names></name><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gressler</surname><given-names initials="LE">Laura Elisabeth</given-names></name><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hu</surname><given-names initials="B">Bo</given-names></name><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Williams</surname><given-names initials="JS">James Silas</given-names></name><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-8402-3098</contrib-id><name name-style="western"><surname>Martin</surname><given-names initials="BC">Bradley C.</given-names></name><xref rid="A3" ref-type="aff">3</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Biomedical Informatics, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA</aff><aff id="A2"><label>2</label>Center for Mental Healthcare and Outcomes Research, Central Arkansas Veterans Healthcare System, Little Rock, Arkansas, USA</aff><aff id="A3"><label>3</label>Division of Pharmaceutical Evaluation and Policy, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA</aff><author-notes><corresp id="CR1"><bold>Correspondence</bold>: Bradley C. Martin, Division of Pharmaceutical Evaluation and Policy, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR, USA. <email>bmartin@uams.edu</email></corresp><fn fn-type="COI-statement" id="FN1"><p id="P33">CONFLICTS OF INTEREST</p><p id="P34">Dr. Martin receives royalties from TrestleTree LLC for the commercialization of an opioid risk prediction tool, which is unrelated to the current study. Dr. Martin is a paid consultant for eMaxHealth Systems for unrelated projects.</p></fn></author-notes><pub-date pub-type="ppub"><month>10</month><year>2022</year></pub-date><pub-date pub-type="epub"><day>30</day><month>6</month><year>2022</year></pub-date><volume>31</volume><issue>10</issue><issue-id pub-id-type="pmc-issue-id">432211</issue-id><fpage>1075</fpage><lpage>1090</lpage><pub-history><event event-type="nihms-submitted"><date><day>21</day><month>03</month><year>2023</year></date></event><event event-type="pmc-release"><date><day>29</day><month>03</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>29</day><month>03</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-06-15 05:25:25.783"><day>15</day><month>06</month><year>2024</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1881734.pdf"/><abstract id="ABS1"><sec id="S1"><title>Purpose:</title><p id="P1">We identified associations between membership in seven group-based trajectories based on supply of filled opioid prescriptions and potential opioid-related adverse health events over a 720-day window.</p></sec><sec id="S2"><title>Methods:</title><p id="P2">We identified two veteran cohorts with chronic non-cancer pain who initiated treatment with long-term opioid therapy between 2008 and 2015, excluding those with prior substance use disorder (<italic toggle="yes">n</italic> = 373 941) or non-SUD, opioid-related adverse outcome (<italic toggle="yes">n</italic> = 405 631) diagnoses. Outcomes of interest included opioid use disorder, non-opioid drug use disorder, and alcohol use disorder for the first cohort; or accidents resulting in wounds or injuries, self-inflicted injuries, opioid-related accidents and overdoses, alcohol and non-opioid drug-related accidents and overdoses, and violence-related injuries for the second cohort. Using a cross-sectional design, Veterans were followed until the specific outcome of interest was diagnosed, they died, the study ended, or they were lost to follow up. Accelerated failure time models were estimated for each outcome.</p></sec><sec id="S3"><title>Results:</title><p id="P3">Membership in persistent moderate days covered and persistent modest days covered trajectories was associated with decreased risk of opioid use disorder (Moderate: &#952; = 0.59, 95%CI:0.54, 0.64; Modest: &#952; = 0.54, 95%CI:0.50, 0.59) and opioid overdose (Moderate: &#952; = 0.67,95%CI: 0.57, 0.79; Modest: &#952; = 0.72, 95%CI:0.61, 0.85) versus higher-utilizing persistent users. Rapid discontinuation was associated with decreased risk of opioid use disorder (&#952; = 0.86, 95% CI:0.77, 0.95) and opioid overdose (&#952; = 0.54, 95%CI:0.41, 0.71), but increased risk of alcohol use disorder (&#952; = 1.07, 95% CI:1.00, 1.15) and other substance use disorders. Delayed discontinuation or delayed reduction was associated with increased risk for most opioid related adverse health events.</p></sec><sec id="S4"><title>Conclusion:</title><p id="P4">Persistent use trajectories with low levels of opioid utilization were associated with lower risks of potential opioid-related adverse health events.</p></sec></abstract><abstract id="ABS2" abstract-type="summary"><title>Plain Language Summary</title><p id="P5">Using data from the Veterans Health Administration, we classified veterans with chronic pain into one of seven trajectories based on days&#8217; supply of opioid prescriptions over a two-year period. We followed these veterans over the same two-year period until they had a specific outcome of interest (i.e., opioid use disorder, non-opioid drug use disorder, alcohol use disorder, accident resulting in wounds or injuries, self-inflicted injury, opioid-related accident or overdose, alcohol and non-opioid drug-related accident or overdose, or violence-related injury), died, were lost to follow-up, or the study ended. Membership in persistent moderate days covered and persistent modest days covered trajectories was associated with decreased risk of opioid use disorder and opioid overdose versus those following the persistent, high days covered trajectory. Rapid discontinuation was associated with decreased risk of opioid use disorder and opioid overdose, but increased risk of alcohol use disorder and other substance use disorders. Delayed discontinuation or delayed reduction was associated with increased risk for most opioid related adverse health events. Persistent use trajectories with low levels of opioid days&#8217; supply were associated with lower risks of opioid-related adverse health events.</p></abstract><kwd-group><kwd>group-based trajectories</kwd><kwd>long-term opioid therapy</kwd><kwd>opioid-related adverse outcomes</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>